Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 10/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5184459 | 0.84 | NFE2L2 (0.53) | NFE2L2 | |
| SCHEMBL10448958 | 0.83 | TAAR1 (0.47) | NFE2L2MAOBTDP1 | |
| SCHEMBL8112257 | 0.78 | NFE2L2 (0.50) | NFE2L2 | |
| SCHEMBL23457275 | 0.75 | NFE2L2 (0.56) | NFE2L2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3713124 | 0.75 | NFE2L2 (0.56) | NFE2L2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15941726 | 0.74 | TRPA1 (0.47) | NFE2L2MAOBTDP1CA1CA2 | |
| SCHEMBL9355230 | 0.74 | ALDH1A1 (0.46) | MAOBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9355554 | 0.74 | MAOB (0.46) | MAOBTDP1CA1CA2ARG2 | |
| SCHEMBL1759710 | 0.73 | NFE2L2 (0.54) | NFE2L2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL10928052 | 0.72 | NFE2L2 (0.43) | NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | claimed |
| EP-0687686-B1 | AUREOBASIDINS | TAKARA SHUZO CO (JP) | 2000-08-30 | — | — | EP | claimed |
| US-5200417-A | Administering to inhibait gastric acid secretion in mammals | SMITHKLINE BEECHAM INTERCREDIT B.V. (GB) | 1993-04-06 | — | — | US | claimed |
| CN-113924294-A | Microbicidal derivatives | 先正达农作物保护股份公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-0687686-B1 | AUREOBASIDINS | TAKARA SHUZO CO (JP) | 2000-08-30 | — | — | EP | disclosed |
| US-6030975-A | ANTAGONIST OF ENDOTHELINS, I.E. INHIBITION OF BINDING WITH RECEPTOR; ANTITUMOR AND -CARCINOGENIC AGENTS; SIDE EFFECT REDUCTION | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| US-5840722-A | ADMINISTERING TO INHIBIT ENDOTHELIN RECEPTORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-11-24 | — | — | US | disclosed |
| US-5703017-A | HERBICIDES, PLANT GROWTH REGULATORS | BASF AKTIENGESELLSCHAFT (DE) | 1997-12-30 | — | — | US | disclosed |
| CN-1121711-A | 3-(hetero)aryl carboxylic acid derivatives, methods of preparing them and intermediates used in their preparation | BASF AG (DE) | 1996-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP7 | NFE2L2 3296/4885MAOB 713/4885TDP1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.